ArticleJournal of pathology informatics2020
A Validation Study of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Digital Imaging Analysis and its Correlation with Human Epidermal Growth Factor Receptor 2 Fluorescence
Article in Journal of pathology informatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Artificial Intelligence for Diagnostic and Prognostic Support in Breast Cancer: A Literature Overview.Cancers · 2026Review
- Analysis of Large Language Model Decision Making in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.JCO clinical cancer informatics · 2026Article
- New standards in HER2-low testing: the CASI-01 comparative methods study.EBioMedicine · 2025Article
- Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine.European journal of breast health · 2025Article
- Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.Virchows Archiv : an international journal of pathology · 2025Article
- EpidermaQuant: Unsupervised Detection and Quantification of Epidermal Differentiation Markers on H-DAB-Stained Images of Reconstructed Human Epidermis.Diagnostics (Basel, Switzerland) · 2024Article
- Revolutionizing Pathology with Artificial Intelligence: Innovations in Immunohistochemistry.Journal of personalized medicine · 2024Review
- Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.Breast cancer research and treatment · 2024Article
- Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.Cancers · 2024Review
- Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.Breast cancer research : BCR · 2024Article
- Artificial intelligence's impact on breast cancer pathology: a literature review.Diagnostic pathology · 2024Review
- European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development.Toxicologic pathology · 2023Review
- HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.International journal of molecular sciences · 2023Review
- Artificial intelligence applied to breast pathology.Virchows Archiv : an international journal of pathology · 2022Review
- Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study.Virchows Archiv : an international journal of pathology · 2021Article
- Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association.Applied immunohistochemistry & molecular morphology : AIMM · 2021Article
- Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.Breast cancer research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Visiopharm human epidermal growth factor receptor 2 (HER2) digital imaging analysis (DIA) algorithm assesses digitized HER2 immunohistochemistry (IHC) by measuring cell membrane connectivity. We aimed to validate this algorithm for clinical use by comparing with pathologists' scoring and correlating with HER2 fluorescence MATERIALS AND
methodsThe study cohort consisted of 612 consecutive invasive breast carcinoma specimens including 395 biopsies and 217 resections. HER2 IHC slides were scanned using Philips IntelliSite Scanners, and the digital images were analyzed using Visiopharm HER2-CONNECT App to obtain the connectivity values (0-1) and scores (0, 1+, 2+, and 3+). HER2 DIA scores were compared with Pathologists' manual scores, and HER2 connectivity values were correlated with
resultsThe concordance between HER2 DIA scores and pathologists' scores was 87.3% (534/612). All discordant cases (
conclusionsHER2 IHC DIA demonstrates excellent concordance with pathologists' scores and accurately discriminates between
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.